Patents by Inventor Rodney L. Levine

Rodney L. Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220105186
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: November 2, 2021
    Publication date: April 7, 2022
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Publication number: 20200188515
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 18, 2020
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Patent number: 10683316
    Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 16, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Trustees of Boston University
    Inventors: John C. Kash, Jeffery K. Taubenberger, Rodney L. Levine, Susan Doctrow
  • Patent number: 10342871
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: July 9, 2019
    Assignees: The Henry Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Publication number: 20160199408
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: October 22, 2015
    Publication date: July 14, 2016
    Inventors: Michael J. DALY, Elena K. GAIDAMAKOVA, Vera Y. MATROSOVA, Rodney L. LEVINE, Nancy B. WEHR
  • Patent number: 9186406
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: November 17, 2015
    Assignees: The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Publication number: 20140341876
    Abstract: Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a defensin polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD), are described. The polypeptide and/or NAD can be administered via inhalation. Also disclosed is a pharmaceutical composition including at least one defensin polypeptide and NAD. In vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide, are also described.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Joel Moss, Linda Stevens, Rodney L. Levine
  • Publication number: 20140329792
    Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    Type: Application
    Filed: November 9, 2012
    Publication date: November 6, 2014
    Inventors: John C. Kash, Jeffery K. Taubenberger, Rodney L. Levine, Susan Doctrow
  • Patent number: 8828380
    Abstract: Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Moss, Linda Stevens, Rodney L. Levine
  • Patent number: 8609607
    Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: December 17, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
  • Publication number: 20120164123
    Abstract: Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide.
    Type: Application
    Filed: September 8, 2010
    Publication date: June 28, 2012
    Inventors: Joel Moss, Linda Stevens, Rodney L. Levine
  • Publication number: 20120107336
    Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
    Type: Application
    Filed: January 5, 2012
    Publication date: May 3, 2012
    Inventors: Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
  • Patent number: 8106006
    Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: January 31, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
  • Publication number: 20110183021
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: August 18, 2008
    Publication date: July 28, 2011
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Metrosova, Rodney L. Levine, Nancy B. Wehr
  • Publication number: 20100041060
    Abstract: The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Applicants: LOMA LINDA UNIVERSITY MEDICAL CENTER, HEALTH AND HUMAN SERVICES, UNITED STATE OF AMERICA REPRESENTED BY THE SECCRETARY
    Inventors: WOLFF M. KIRSCH, ANTON LENNART, WAYNE J. KELLN, DAE-KYUNG KANG, RODNEY L. LEVINE, TRACEY A. ROUAULT
  • Publication number: 20090155293
    Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method if provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 18, 2009
    Inventors: Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
  • Patent number: 7511015
    Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method is provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: March 31, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
  • Publication number: 20020165349
    Abstract: The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease.
    Type: Application
    Filed: August 6, 2001
    Publication date: November 7, 2002
    Inventors: Wolff M. Kirsch, Anto Lennart, Wayne J. Kelln, Dae-Kyung Kang, Rodney L. Levine, Tracey A. Rouault